We are a joint venture formed of Reig Jofre and LeanBio to develop high quality biosimilars and innovative molecules to respond to the growing global demand for biological treatments. At Syna we cover the entire value chain to enable biosimilars to reach patients: - Cell bank creation - Pharma development of the finished product - Industrial production - Marketing or licence agreements It is therefore crucial to have the scientific know-how in the field provided by LeanBio, founded by Dr. Andreu Soldevila in 2014, and the experience of the Reig Jofre group in the formulation, stabilisation and pharmaceutical development of biological, injectable and lyophilised products. Reig Jofre currently has a network of 130 business partners and is present in more than 70 countries.